Oncotelic's $1.7B Pipeline Valuation Signals Nanomedicine's Rising Potential

NEW YORK, NY – November 20, 2025

A Billion-Dollar Bet on Targeted Therapy

Oncotelic Therapeutics, Inc. (OTLC) has announced a preliminary valuation of $1.7 billion for the pipeline of its joint venture with GMP Bio, a figure that underscores the growing investor interest in cutting-edge nanomedicine and targeted cancer therapies. The valuation, conducted by Frost & Sullivan (Hong Kong), estimates Oncotelic’s 45% ownership stake at approximately $765 million. While the valuation is preliminary and not fully compliant with U.S. GAAP standards, it offers a compelling snapshot of the potential inherent in the joint venture's development programs, particularly its lead candidate, OT-101, and the broader Deciparticle™ nanomedicine platform.

“This valuation is a significant milestone for Oncotelic, providing an initial indication of the potential value locked within this collaborative venture,” noted one industry analyst familiar with the company’s strategy. “The market is clearly recognizing the potential of targeted therapies and the innovative approach Oncotelic is taking with its Deciparticle technology.”

Deciparticle™: Disrupting Drug Delivery

The Deciparticle™ platform is at the heart of the joint venture's pipeline. Utilizing nanotechnology, it aims to improve drug delivery by encapsulating therapeutic agents within nanoparticles that can precisely target cancer cells while minimizing systemic toxicity. This targeted approach is crucial in overcoming the limitations of traditional chemotherapy, which often affects healthy cells alongside cancerous ones.

OT-101, the lead candidate, is currently in Phase 3 clinical trials for pancreatic ductal adenocarcinoma (PDAC), a particularly aggressive and difficult-to-treat cancer. The success of this trial will be pivotal in establishing the platform's efficacy and driving further development. The joint venture is also exploring combination studies involving OT-101, aiming to enhance its therapeutic effect by pairing it with other cancer treatments.

“The platform’s potential goes beyond simply delivering drugs,” explained a researcher specializing in nanomedicine. “It can also be used to deliver gene therapies, immune stimulants, and other therapeutic modalities, opening up a wide range of possibilities for treating various diseases.”

The Hong Kong IPO and a Growing Biotech Hub

The joint venture is actively preparing for a potential Initial Public Offering (IPO) on the Hong Kong Stock Exchange in late 2026. This move aligns with Hong Kong’s ambition to become a leading global hub for biotechnology innovation, spurred by regulatory reforms allowing pre-revenue biotech companies to list. The HKEX has streamlined listing processes and introduced features to attract biotech firms, creating a favorable environment for fundraising and growth.

“Hong Kong offers a compelling alternative to the U.S. market for biotech companies,” noted an investment banker specializing in biotech IPOs. “The regulatory environment is supportive, and there is a growing pool of investors interested in innovative healthcare technologies.”

The anticipated IPO could provide the joint venture with the capital needed to accelerate its clinical development programs, expand its manufacturing capacity, and further refine the Deciparticle™ platform. It also offers a potential exit strategy for early investors and could unlock substantial value for Oncotelic shareholders. However, navigating the complexities of an IPO and maintaining a positive market reception will be crucial to the venture’s success.

GMP Bio: A Focused Operational Partner

GMP Bio, the joint venture partner, brings essential manufacturing capabilities to the collaboration. With a fully operational GMP-licensed facility in San Diego, the venture can control the production of its therapeutics, ensuring quality and consistency. This in-house manufacturing capability is a significant advantage, reducing reliance on external contract manufacturers and allowing for greater flexibility in scaling up production.

“Having dedicated manufacturing facilities is crucial for a biotech company,” said one observer. “It allows you to control costs, maintain quality, and respond quickly to changes in demand.”

The partnership structure allows Oncotelic to leverage GMP Bio’s operational expertise while focusing its resources on research and development. This division of labor can accelerate the development timeline and improve the overall efficiency of the venture.

The preliminary $1.7 billion valuation is a strong indicator of the potential held within this collaboration, positioning Oncotelic and its partner for continued growth and innovation in the burgeoning field of nanomedicine.